MORPHINE SULFATE (morphine sulfate) by ICU Medical is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 1992.
Drug data last refreshed 5d ago
Morphine sulfate is a mu-opioid receptor agonist indicated for chronic pain, cancer pain, postoperative pain, and neonatal abstinence syndrome. It works by binding to opioid receptors in the CNS with no ceiling effect for analgesia, though dosing is limited by adverse effects like respiratory depression. The drug is administered via injection and has been approved since 1992.
As LOE approaches, the brand team is likely consolidating and focusing on retention strategies; career stability may be challenged by generic competition.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Worked on MORPHINE SULFATE at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on morphine sulfate as LOE approaches offers limited growth but critical experience in mature product management, regulatory maintenance, and cost-containment strategy. This role suits professionals seeking stability over expansion and specializing in legacy asset management and institutional/hospital channels.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo